Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RPA1 | P27694 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 11/20 | 0.43 |
| ▸ | CNR1 | P21554 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766735 | 0.85 | KDM4E (0.52) | SMN1; SMN2CNR2CNR1 | |
| SCHEMBL5768692 | 0.82 | LMNA (0.50) | LMNARPA1CNR2CNR1ALDH1A1 | |
| SCHEMBL6766024 | 0.81 | LMNA (0.46) | LMNARPA1CNR2CNR1ALDH1A1 | |
| SCHEMBL4192493 | 0.80 | CNR2 (0.57) | RPA1CNR2CNR1 | |
| SCHEMBL6770114 | 0.79 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL6770110 | 0.78 | CNR1 (0.50) | CNR2CNR1 | |
| SCHEMBL5769254 | 0.72 | CNR1 (0.45) | CNR2CNR1 | |
| SCHEMBL6770590 | 0.72 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL5768685 | 0.72 | CNR1 (0.45) | LMNARPA1CNR2CNR1ALDH1A1 | |
| SCHEMBL13955259 | 0.71 | LMNA (0.67) | LMNARPA1CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235926-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | LMNA 3194/4885RPA1 4560/4885SMN1; SMN2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.